Abstract: An application of YD1701 in preparation of a drug for treating ALDH1A3 high-expression tumor is disclosed. The YD1701 can be used as an ALDH1A3 inhibitor to reverse the occurrence of epithelial-mesenchymal transition (EMT) of ALDH1A3 high-expression cancer cells. It can reduce tumor invasion and metastasis to inhibit tumor progression and can prolong the overall survival time of tumor-bearring animals. YD1701 have low cytotoxicity.

Abstract: The use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (LPS) and unmethylated DNA (CpG DNA) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use directionally isolates lead compounds from traditional Chinese medicine. These measures can overcome the major defects of uncertainty of pharmacological material basis and drug targets of extracts and constituents of traditional Chinese medicine. The disclosed use can help in developing a safe, effective and quality controllable drug for prevention and treatment of sepsis and autoimmune disease so as to help solve the present lack of effective drugs in clinical treatment.

Abstract: An injectable tissue engineered cartilage in vitro construction apparatus, comprising an incubator (1), a centrifugal device arranged in the incubator (1), and a control system for controlling a temperature in the incubator (1) and an action of the centrifugal device. The centrifugal device comprises a centrifuge, a container base (2) mounted onto the centrifuge, a dosing system for adding preparation reagent, and a stirring system for stirring the reagent. With a controller (17) and a pH sensor (16), a measured pH value will be transmitted by the pH sensor (16) to the controller (17) in real time. The controller (17) controls an action of a driving mechanism via a control module II (21), to drive a piston rod to add NaOH solution into a container tank (6). When the pH value of the solution falls in a predetermined range, the driving mechanism is stopped, to precisely control the pH value of the solution.

Abstract: Provided is staphylococcus protein A expressed by a mutational Staphylococcus aureus and its coding sequence, as well as a vector, host bacteria, composition or kit which contains the coding sequence of the mutational protein. Also provided is the use of the mutational protein and the composition thereof in the preparation of vaccines, therapeutic antibodies, diagnostic kits and the like, and for the prevention, treatment and detection of infections by Staphylococcus aureus. Also provided are methods for producing, fermenting and purifying the mutational protein.

Abstract: The invention discloses application of irisin in the preparation of drugs for preventing myocardial ischemia reperfusion injuries. Experimental results show that irisin can decrease the myocardial infarction area caused by ischemia reperfusion, reduce the increase of the contents of lactate dehydrogenase (LDH), troponin (cTnI), creatine kinase (CK), and other myocardial enzyme markers caused by ischemia reperfusion, meanwhile reducing the inflammatory response, myocardial apoptosis, and oxidative stress response caused by myocardial ischemia reperfusion, promote peroxysome proliferator-activated receptor ? nuclear translocation, and inhibit nuclear transcription factor NF-?B nuclear translocation and accordingly decrease myocardial structure injuries and load increase caused by ischemia reperfusion. Therefore, irisin can be used for preventing and decreasing myocardial reperfusion injuries and has important clinical significance on the treatment of myocardial ischemia.

Abstract: The invention discloses an erythropoietin receptor modified electrode, which is a glassy carbon electrode with erythropoietin receptor as recognition element fixed onto the electrode surface via ZnO sol-gel. The modified electrode can be prepared easily, and its performance is stable. After 50-day storage in the dark at 4° C., its response current remained approximately 77% of the original value. An electrochemical biosensor using this modified electrode as working electrode, a platinum electrode as counter electrode, a saturated calomel electrode as reference electrode, and 2 mmol/L K3[Fe(CN)6]—K4[Fe(CN)6]phosphate buffer as the test base solution, can detect erythropoietin (EPO) and/or recombinant human erythropoietin (rhEPO) in a fast, specific, and sensitive manner, with a linear range of 5 pg/L-500 ng/L and a limit of detection of 0.5 pg/L. In particular, according to peak potential differences, the biosensor allows accurate discrimination of EPO and rhEPO.

Abstract: The invention discloses an erythropoietin receptor modified electrode, which is a glassy carbon electrode with erythropoietin receptor as recognition element fixed onto the electrode surface via ZnO sol-gel. The modified electrode can be prepared easily, and its performance is stable. After 50-day storage in the dark at 4° C., its response current remained approximately 77% of the original value. An electrochemical biosensor using this modified electrode as working electrode, a platinum electrode as counter electrode, a saturated calomel electrode as reference electrode, and 2 mmol/L K3[Fe(CN)6]-K4[Fe(CN)6] phosphate buffer as the test base solution, can detect erythropoietin (EPO) and/or recombinant human erythropoietin (rhEPO) in a fast, specific, and sensitive manner, with a linear range of 5 pg/L-500 ng/L and a limit of detection of 0.5 pg/L. In particular, according to peak potential differences, the biosensor allows accurate discrimination of EPO and rhEPO.

Abstract: Provided are a series of Gq protein competitive inhibitory polypeptides (GCIPs), polynucleotides encoding them, and preparation methods thereof. Also provided are pharmaceutical compositions comprising GCIP polypeptides and their uses in the manufacture of drugs for treating myocardial hypertrophy.

Abstract: The use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (LPS) and unmethylated DNA (CpG DNA) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use directionally isolates lead compounds from traditional Chinese medicine. These measures can overcome the major defects of uncertainty of pharmacological material basis and drug targets of extracts and constituents of traditional Chinese medicine. The disclosed use can help in developing a safe, effective and quality controllable drug for prevention and treatment of sepsis and autoimmune disease so as to help solve the present lack of effective drugs in clinical treatment.

Abstract: The present invention discloses a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treatment of urogenital tract infection. N-acetyl-D-glucosamine exhibits a function of suppressing the transplantation of exotic microorganisms and promoting the repair of topical skin tissue, and the formulation comprising it as a main active component is used for the prevention and treatment of urogenital tract infection and has advantages such as notable therapeutic effect, easy preparation, non-irritation, non-contamination, etc.

Abstract: The present invention is directed to the use of N-acetyl-D-glucosamine to treat organ lesions caused by toxicants and drugs. The present invention is also directed to a method for treating organ lesions caused by toxicant comprising administering to a patient suffering from organ lesions a pharmaceutical composition comprising N-acetyl-D-glucosamine or a pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses a use of N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating local lesions or systematic symptoms caused by infections of virus or bacteria. A parenteral preparation comprising N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof as active component is capable of controlling systematic toxic symptoms caused by infections of virus and bacteria and local and systematic lesions caused by endotoxins and exotoxins, and exhibits an excellence rate of 90%.

Abstract: The present invention has disclosed a use of N-acetyl-D-glucosamine in the manufacture of a medicament for resisting cardiac and cerebral ischemia and oxygen-deficiency. N-acetyl-D-glucosamine can obviously prolong the survival time of the experimental animal under the condition of cerebral ischemia and oxygen-deficiency at normal pressure, can decrease cerebral edema degree and other symptoms of the nerve behavior caused by cerebral ischemia and re-infusion.

Abstract: The present invention has disclosed a use of N-acetyl-D-glucosamine in the manufacture of a medicament for inhibiting the side effect of radio-chemical therapy, the medicament with N-acetyl-D-glucosamine as main active component can be used to inhibit the side effect of radio-chemical therapy of cancer patients, with an effective rate up to 85%.

Abstract: The present invention has disclosed a use of N-acetyl-D-glucosamine in the preparation of a medicine for preventing and treating the sexual disfunction. The preparation taken N-acetyl-D-glucosamine as a main active component has been used to prevent and cure the sexual disfunction, and has the merits of remarkable curative effect, easy to prepare, no side effect and so on.

Abstract: The present invention has disclosed the use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating cervical erosion. N-acetyl-D-glucosamine can resist the field planting of microorganism and control microorganism infection, and improve the symptoms of local exudation, tissue inflammatory oedema and pain and the like.

Abstract: The present invention has disclosed a use of N-acetyl-D-glucosamine in the manufacture of a medicament for preventing and treating motion sickness, the preparation in which N-acetyl-D-glucosamine is taken as a main active component is able to be used for preventing and treating motion sickness with an effective rate up to more than 90%.

Abstract: A kit for the anastomosing of a blood vessel which includes a pair of anastomic wheels. Each wheel has an axially extending hollow body for the passing of a blood vessel therethrough and a peripheral extending flange. The periphery of the flange has a plurality of forwardly extending pins for piercing and holding the wall of a blood vessel passing through the hollow body and stretched outwardly across the flange and impaled on the pins, the wheels with the blood vessel end impaled on the pins thereof being brought together with the flanges abutting and the projecting pins on the flanges being bent over the opposing flange with the stretched blood vessel wall therebetween to join the blood vessel walls. Also included are a hook and pressing needle for stretching and impaling the blood vessel ball on the pins; and clasping pliers for clasping the wheels and bending the pins.